The application of IVIg started based on the finding that Fas-mediated keratinocyte apoptosis could be inhibited by human IVIg products in vitro, and no mortality was observed in a pilot study that administered IVIg to 10 TEN patients (Viard et al., 1998). Here, FAS is linked to toxic epidermal necrolysis.